


Cloperastine fendizoate

Cat. No.:	HY-B2179
CAS No.:	85187-37-7
Molecular Formula:	C ₄₀ H ₃₈ ClNO ₅
Molecular Weight:	648.19
Target:	Potassium Channel
Pathway:	Membrane Transporter/Ion Channel
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 10 mg/mL (15.43 mM; Need ultrasonic)				
	Preparing Stock Solutions	Mass	1 mg	5 mg	10 mg
		Solvent			
		Concentration			
		1 mM	1.5428 mL	7.7138 mL	15.4276 mL
In Vivo		5 mM	0.3086 mL	1.5428 mL	3.0855 mL
		10 mM	0.1543 mL	0.7714 mL	1.5428 mL
	Please refer to the solubility information to select the appropriate solvent.				
	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1 mg/mL (1.54 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1 mg/mL (1.54 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1 mg/mL (1.54 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Cloperastine fendizoate inhibits the hERG K ⁺ currents in a concentration-dependent manner with an IC ₅₀ value of 27 nM.
IC ₅₀ & Target	27 nM (K ⁺ currents) ^[1]
In Vitro	Cloperastine inhibits the hERG K ⁺ currents in a concentrationdependent manner with IC ₅₀ value of 27±3 nM ^[1] . Among the antitussive agents, Cloperastine, which possesses antitussive and antiedemic activity, also relaxes the bronchial musculature. Cloperastine is a drug with a central antitussive effect, and is also endowed with an antihistaminic and

	<p>papaverine-like activity similar to codeine but without its narcotic effects^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
In Vivo	<p>In the anesthetized guinea pigs, Cloperastine at a therapeutic dose of 1 mg/kg prolonged the QT interval and monophasic action potential (MAP) duration without affecting PR interval or QRS width^[1]. Cloperastine hydrochloride shows relatively low acute toxicity when administered by the intraperitoneal route in rats and mice, and shows minor toxicity by the oral route when administered as Cloperastine fenzate, the LD₅₀ in rats and mice for the two administration routes exceeds 1000 and 2000 mg/kg, respectively^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

- [1]. Takahara A, et al. Effects of the antitussive drug cloperastine on ventricular repolarization in halothane-anesthetized guinea pigs. J Pharmacol Sci. 2012;120(3):165-75.
- [2]. Catania MA, et al. Pharmacological and clinical overview of cloperastine in treatment of cough. Ther Clin Risk Manag. 2011;7:83-92.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA